Genetic Variants Linked to CAR T-Cell Efficacy and Safety

Researchers have discovered a link between specific genetic variants and the performance of CAR T-cell therapy in cancer patients. Published in Science Immunology, this work identifies three genes that dictate both the effectiveness of the treatment and the severity of side effects. Because CAR T-cell therapy uses a patient’s own immune cells, the unique genetic makeup of the individual plays a major role in how the treatment functions.

The study involved 236 patients with aggressive lymphoma who received axicabtagene ciloleucel. By performing whole-genome sequencing alongside biomarker analysis, the research team found that variants in the STXBP2 gene often appear in patients who experience higher toxicity levels. These variants lead to increased cytokine production and greater macrophage activation.

Conversely, the research identified protective factors. Variants in the ADMTSL3 gene seem to help patients avoid treatment-related toxicity. Furthermore, variants in the PTPN22 gene are associated with better CAR T-cell expansion, which directly contributes to the success of the therapy.

This insight is a move toward precision medicine for cancer immunotherapy. Since CAR T cells are bespoke, understanding these genetic markers allows for better patient management. The authors, led by Dr. Marcela V. Maus of Massachusetts General Hospital, suggest this data will also assist in developing off-the-shelf therapies. By selecting donor cells with beneficial genetic profiles, doctors may be able to increase success rates and safety for future recipients.